NR 567 Advanced Pharmacology for the AGACNP: Ultimate
Midterm Exam Review Study Guide
Master your Chamberlain University NR 567 Midterm Exam with this
premium, high-density study guide featuring course-aligned multiple-choice
questions. Aligned perfectly with the Adult-Gerontology Acute Care Nurse
Practitioner (AGACNP) core curriculum, this guide targets weeks 1–4
advanced pharmacology content including critical care vasoactive titration,
high-alert cardiac regimens, and complex drug interactions. Complete with
bolded correct answers and deeply detailed, step-by-step clinical
rationales, this high-yield resource guarantees a streamlined path to
achieving a Grade A on your midterm.
Question 1
A 65-year-old patient in the intensive care unit experiencing severe septic shock
exhibits persistent hypotension despite adequate fluid resuscitation. The acute care
nurse practitioner initiates a continuous intravenous infusion of norepinephrine. What is
the primary molecular mechanism of action driving this drug's therapeutic benefit?
A. Selective beta-1 adrenergic receptor agonism to maximize myocardial contractility
B. Potent alpha-1 adrenergic receptor agonism inducing profound peripheral
vasoconstriction
C. Direct stimulation of endothelial nitric oxide synthase to reduce systemic afterload
D. Activation of dopaminergic D1 receptors to optimize mesenteric blood perfusion
Answer: B. Potent alpha-1 adrenergic receptor agonism inducing profound
peripheral vasoconstriction
Rationale: Per the Surviving Sepsis Campaign guidelines, norepinephrine is the first-line
vasoactive agent for septic shock. It functions primarily as a potent alpha-1 adrenergic
receptor agonist, causing widespread systemic vasoconstriction that increases systemic
vascular resistance (SVR) and elevates blood pressure. While it possesses minor beta-
1 activity, its alpha-1 vasoconstrictive effects dominate in treating vasodilatory shock.
Question 2
An acute care clinical team is evaluating a patient with severe hepatic cirrhosis who is
experiencing recurrent esophageal variceal bleeding. Which of the following explains
why non-selective beta-blockers like propranolol are prescribed in this population?
A. They increase cardiac output to maximize visceral organ perfusion.
B. They reduce portal vein hypertension by causing splanchnic vasoconstriction via
unopposed alpha-1 stimulation.
,C. They selectively dilate hepatic sinusoids to reduce resistance.
D. They accelerate the conversion of fibrinogen to localized fibrin clots.
Answer: B. They reduce portal vein hypertension by causing splanchnic
vasoconstriction via unopposed alpha-1 stimulation.
Rationale: In patients with portal hypertension and esophageal varices secondary to
cirrhosis, non-selective beta-blockers (propranolol or nadolol) are used for primary and
secondary prophylaxis against bleeding. They work by blocking beta-2 receptors in the
splanchnic vasculature, leaving alpha-1 receptors unopposed. This triggers splanchnic
vasoconstriction, which reduces portal blood flow and directly lowers portal venous
pressure.
Question 3
A patient with chronic systolic heart failure is being managed on an optimal drug
regimen. The provider decides to initiate spironolactone therapy. The acute care nurse
practitioner must monitor the patient closely for which life-threatening drug interaction if
the patient is already taking an Angiotensin-Converting Enzyme Inhibitor (ACEI)?
A. Severe hypercalcemia and metabolic alkalosis
B. Profound hypokalemia leading to prolonged QT intervals
C. Severe hyperkalemia due to additive potassium retention
D. Acute respiratory alkalosis from pulmonary congestion
Answer: C. Severe hyperkalemia due to additive potassium retention
Rationale: Spironolactone is a potassium-sparing aldosterone antagonist that prevents
potassium excretion in the distal renal tubules and collecting ducts. ACE inhibitors block
the production of angiotensin II, which naturally reduces aldosterone secretion and
causes potassium retention. Combining an ACEI with spironolactone poses a high risk
for additive hyperkalemia, requiring close monitoring of serum potassium levels.
Question 4
A patient with a documented history of coronary artery disease and transient ischemic
attacks (TIAs) requires antiplatelet therapy for secondary stroke prevention. The patient
has a verified history of a severe, true anaphylactic allergy to aspirin. Which of the
following options represents the most appropriate, first-line alternative agent?
A. Ketorolac tromethamine
B. Clopidogrel bisulfate
C. Dipyridamole monotherapy
D. High-dose Indomethacin
Answer: B. Clopidogrel bisulfate
Rationale: For patients who cannot tolerate aspirin due to a documented allergy or
severe hypersensitivity, clopidogrel is the standard first-line antiplatelet alternative for
secondary prevention of vascular events. Clopidogrel functions by irreversibly blocking
P2Y12 adenosine diphosphate (ADP) receptors on platelets, inhibiting aggregation via a
separate biochemical pathway than aspirin.
Question 5
A patient presents to the clinic with severe, painful allergic conjunctivitis. When
educating the patient on the initiation of an ophthalmic mast cell stabilizer, what critical
timing parameter must the clinician emphasize regarding its clinical efficacy?
A. The medication will provide complete relief within 5 minutes of the first drop.
B. It acts as an acute rescue agent and should only be used as needed for immediate
,flare-ups.
C. It may require several days of continuous use to see the onset of effect, and up to
two weeks for maximum therapeutic benefit.
D. The drop must be washed out with normal saline within 10 minutes of application.
Answer: C. It may require several days of continuous use to see the onset of
effect, and up to two weeks for maximum therapeutic benefit.
Rationale: Mast cell stabilizers (such as nedocromil or cromolyn sodium) prevent the
degranulation of mast cells and the subsequent release of inflammatory mediators like
histamine. They are prophylactic agents rather than rescue drugs. Patients must be
educated that these medications have a slow onset of clinical action, often taking
several days to demonstrate an effect and up to two weeks of continuous therapy to
achieve maximum therapeutic relief.
Question 6
A patient with chronic open-angle glaucoma requires advanced pharmacological
management to lower intraocular pressure. Which of the following groups of
medications are correctly classified as agents that reduce intraocular pressure by
specifically decreasing the production of aqueous humor?
A. Miotics, osmotic diuretics, and prostaglandin analogs
B. Beta-blockers, alpha-2 adrenergic agonists, and carbonic anhydrase inhibitors
C. Muscarinic antagonists, loop diuretics, and alpha-1 agonists
D. Rho-kinase inhibitors and nitric oxide donating compounds
Answer: B. Beta-blockers, alpha-2 adrenergic agonists, and carbonic anhydrase
inhibitors
Rationale: Managing open-angle glaucoma involves either increasing the outflow of
aqueous humor or decreasing its production. Beta-blockers (e.g., timolol), alpha-2
agonists (e.g., brimonidine), and carbonic anhydrase inhibitors (e.g., dorzolamide) lower
intraocular pressure by acting directly on the ciliary body to decrease the overall rate of
aqueous humor synthesis.
Question 7
A 55-year-old male with a history of mechanical aortic valve replacement is being
transitioned from an intravenous heparin infusion to oral warfarin sodium. The provider
checks the daily laboratory results and notes that the prothrombin time (PT) has
increased, but the International Normalized Ratio (INR) is 1.2. Which of the following
actions is the most appropriate next step?
A. Stop the heparin infusion immediately because the PT is elevated.
B. Continue the heparin infusion and maintain the current warfarin dose, as the INR has
not reached the therapeutic target range.
C. Administer an immediate dose of vitamin K1 to prevent spontaneous hemorrhage.
D. Switch the patient from warfarin to a direct oral anticoagulant (DOAC) like apixaban.
Answer: B. Continue the heparin infusion and maintain the current warfarin dose,
as the INR has not reached the therapeutic target range.
Rationale: When transitioning a patient from heparin to warfarin, "bridging" therapy is
required because warfarin has a delayed onset of action, taking several days to deplete
functional vitamin K-dependent clotting factors (II, VII, IX, X). The heparin infusion must
be continued concurrently until the INR reaches the designated therapeutic target range
(typically 2.5–3.5 for a mechanical aortic valve) and remains stable for at least 24 hours.
, Question 8
An acute care nurse practitioner is preparing to initiate an intravenous loading dose of
amiodarone for a patient experiencing an acute onset of hemodynamically stable
ventricular tachycardia. Which of the following baseline organ assessments is a priority
before initiating chronic maintenance therapy with this class III antiarrhythmic?
A. Pulmonary function tests and thyroid panel evaluation
B. Serological amylase and lipase profiles
C. Serum uric acid and joint fluid analysis
D. Structural bone mineral density scanning
Answer: A. Pulmonary function tests and thyroid panel evaluation
Rationale: Amiodarone is an iodine-rich medication that carries severe boxed warnings
for cumulative organ toxicity. It can cause fatal pulmonary toxicity (interstitial
pneumonitis or fibrosis) and significant thyroid dysfunction (hypothyroidism or
hyperthyroidism) due to its structural iodine content and inhibitory effects on thyroid
hormone conversion. Baseline and periodic pulmonary function tests (PFTs) and thyroid
panels are mandatory.
Question 9
A patient admitted with an acute myocardial infarction develops severe bradycardia with
a heart rate of 35 beats per minute and signs of hemodynamic compromise. The acute
care practitioner administers intravenous atropine sulfate. What is the molecular
mechanism of action of this drug?
A. Direct stimulation of beta-1 adrenergic receptors in the SA node
B. Competitive antagonism of muscarinic acetylcholine receptors blocking vagal tone
C. Inhibition of acetylcholinesterase to increase synaptic acetylcholine accumulation
D. Activation of peripheral alpha-1 receptors to cause compensatory vasoconstriction
Answer: B. Competitive antagonism of muscarinic acetylcholine receptors
blocking vagal tone
Rationale: Atropine is an anticholinergic medication that acts as a competitive
antagonist at muscarinic acetylcholine receptors. In symptomatic bradycardia, it blocks
the parasympathetic (vagal) input to the sinoatrial (SA) and atrioventricular (AV) nodes.
This inhibition removes the vagal brake on the heart, resulting in an increased sinus
heart rate and accelerated AV nodal conduction.
Question 10
A patient in the intensive care unit requires deep sedation and is prescribed a
continuous intravenous infusion of propofol. Which of the following metabolic monitoring
parameters must be closely evaluated due to the unique lipid emulsion formulation of
this anesthetic agent?
A. Serum uric acid and purine profiles
B. Serum triglycerides and total calorie counts from lipids
C. Blood urea nitrogen and creatinine clearance ratios
D. Serum calcium and parathyroid hormone levels
Answer: B. Serum triglycerides and total calorie counts from lipids
Rationale: Propofol is formulated in a phospholipid lipid emulsion containing soybean oil
and egg phosphatide, which delivers approximately 1.1 kcal/mL of fat. Prolonged or
high-dose infusions can cause significant hypertriglyceridemia and place the patient at
risk for propofol infusion syndrome (PRIS) or acute pancreatitis. Serum lipid panels
Midterm Exam Review Study Guide
Master your Chamberlain University NR 567 Midterm Exam with this
premium, high-density study guide featuring course-aligned multiple-choice
questions. Aligned perfectly with the Adult-Gerontology Acute Care Nurse
Practitioner (AGACNP) core curriculum, this guide targets weeks 1–4
advanced pharmacology content including critical care vasoactive titration,
high-alert cardiac regimens, and complex drug interactions. Complete with
bolded correct answers and deeply detailed, step-by-step clinical
rationales, this high-yield resource guarantees a streamlined path to
achieving a Grade A on your midterm.
Question 1
A 65-year-old patient in the intensive care unit experiencing severe septic shock
exhibits persistent hypotension despite adequate fluid resuscitation. The acute care
nurse practitioner initiates a continuous intravenous infusion of norepinephrine. What is
the primary molecular mechanism of action driving this drug's therapeutic benefit?
A. Selective beta-1 adrenergic receptor agonism to maximize myocardial contractility
B. Potent alpha-1 adrenergic receptor agonism inducing profound peripheral
vasoconstriction
C. Direct stimulation of endothelial nitric oxide synthase to reduce systemic afterload
D. Activation of dopaminergic D1 receptors to optimize mesenteric blood perfusion
Answer: B. Potent alpha-1 adrenergic receptor agonism inducing profound
peripheral vasoconstriction
Rationale: Per the Surviving Sepsis Campaign guidelines, norepinephrine is the first-line
vasoactive agent for septic shock. It functions primarily as a potent alpha-1 adrenergic
receptor agonist, causing widespread systemic vasoconstriction that increases systemic
vascular resistance (SVR) and elevates blood pressure. While it possesses minor beta-
1 activity, its alpha-1 vasoconstrictive effects dominate in treating vasodilatory shock.
Question 2
An acute care clinical team is evaluating a patient with severe hepatic cirrhosis who is
experiencing recurrent esophageal variceal bleeding. Which of the following explains
why non-selective beta-blockers like propranolol are prescribed in this population?
A. They increase cardiac output to maximize visceral organ perfusion.
B. They reduce portal vein hypertension by causing splanchnic vasoconstriction via
unopposed alpha-1 stimulation.
,C. They selectively dilate hepatic sinusoids to reduce resistance.
D. They accelerate the conversion of fibrinogen to localized fibrin clots.
Answer: B. They reduce portal vein hypertension by causing splanchnic
vasoconstriction via unopposed alpha-1 stimulation.
Rationale: In patients with portal hypertension and esophageal varices secondary to
cirrhosis, non-selective beta-blockers (propranolol or nadolol) are used for primary and
secondary prophylaxis against bleeding. They work by blocking beta-2 receptors in the
splanchnic vasculature, leaving alpha-1 receptors unopposed. This triggers splanchnic
vasoconstriction, which reduces portal blood flow and directly lowers portal venous
pressure.
Question 3
A patient with chronic systolic heart failure is being managed on an optimal drug
regimen. The provider decides to initiate spironolactone therapy. The acute care nurse
practitioner must monitor the patient closely for which life-threatening drug interaction if
the patient is already taking an Angiotensin-Converting Enzyme Inhibitor (ACEI)?
A. Severe hypercalcemia and metabolic alkalosis
B. Profound hypokalemia leading to prolonged QT intervals
C. Severe hyperkalemia due to additive potassium retention
D. Acute respiratory alkalosis from pulmonary congestion
Answer: C. Severe hyperkalemia due to additive potassium retention
Rationale: Spironolactone is a potassium-sparing aldosterone antagonist that prevents
potassium excretion in the distal renal tubules and collecting ducts. ACE inhibitors block
the production of angiotensin II, which naturally reduces aldosterone secretion and
causes potassium retention. Combining an ACEI with spironolactone poses a high risk
for additive hyperkalemia, requiring close monitoring of serum potassium levels.
Question 4
A patient with a documented history of coronary artery disease and transient ischemic
attacks (TIAs) requires antiplatelet therapy for secondary stroke prevention. The patient
has a verified history of a severe, true anaphylactic allergy to aspirin. Which of the
following options represents the most appropriate, first-line alternative agent?
A. Ketorolac tromethamine
B. Clopidogrel bisulfate
C. Dipyridamole monotherapy
D. High-dose Indomethacin
Answer: B. Clopidogrel bisulfate
Rationale: For patients who cannot tolerate aspirin due to a documented allergy or
severe hypersensitivity, clopidogrel is the standard first-line antiplatelet alternative for
secondary prevention of vascular events. Clopidogrel functions by irreversibly blocking
P2Y12 adenosine diphosphate (ADP) receptors on platelets, inhibiting aggregation via a
separate biochemical pathway than aspirin.
Question 5
A patient presents to the clinic with severe, painful allergic conjunctivitis. When
educating the patient on the initiation of an ophthalmic mast cell stabilizer, what critical
timing parameter must the clinician emphasize regarding its clinical efficacy?
A. The medication will provide complete relief within 5 minutes of the first drop.
B. It acts as an acute rescue agent and should only be used as needed for immediate
,flare-ups.
C. It may require several days of continuous use to see the onset of effect, and up to
two weeks for maximum therapeutic benefit.
D. The drop must be washed out with normal saline within 10 minutes of application.
Answer: C. It may require several days of continuous use to see the onset of
effect, and up to two weeks for maximum therapeutic benefit.
Rationale: Mast cell stabilizers (such as nedocromil or cromolyn sodium) prevent the
degranulation of mast cells and the subsequent release of inflammatory mediators like
histamine. They are prophylactic agents rather than rescue drugs. Patients must be
educated that these medications have a slow onset of clinical action, often taking
several days to demonstrate an effect and up to two weeks of continuous therapy to
achieve maximum therapeutic relief.
Question 6
A patient with chronic open-angle glaucoma requires advanced pharmacological
management to lower intraocular pressure. Which of the following groups of
medications are correctly classified as agents that reduce intraocular pressure by
specifically decreasing the production of aqueous humor?
A. Miotics, osmotic diuretics, and prostaglandin analogs
B. Beta-blockers, alpha-2 adrenergic agonists, and carbonic anhydrase inhibitors
C. Muscarinic antagonists, loop diuretics, and alpha-1 agonists
D. Rho-kinase inhibitors and nitric oxide donating compounds
Answer: B. Beta-blockers, alpha-2 adrenergic agonists, and carbonic anhydrase
inhibitors
Rationale: Managing open-angle glaucoma involves either increasing the outflow of
aqueous humor or decreasing its production. Beta-blockers (e.g., timolol), alpha-2
agonists (e.g., brimonidine), and carbonic anhydrase inhibitors (e.g., dorzolamide) lower
intraocular pressure by acting directly on the ciliary body to decrease the overall rate of
aqueous humor synthesis.
Question 7
A 55-year-old male with a history of mechanical aortic valve replacement is being
transitioned from an intravenous heparin infusion to oral warfarin sodium. The provider
checks the daily laboratory results and notes that the prothrombin time (PT) has
increased, but the International Normalized Ratio (INR) is 1.2. Which of the following
actions is the most appropriate next step?
A. Stop the heparin infusion immediately because the PT is elevated.
B. Continue the heparin infusion and maintain the current warfarin dose, as the INR has
not reached the therapeutic target range.
C. Administer an immediate dose of vitamin K1 to prevent spontaneous hemorrhage.
D. Switch the patient from warfarin to a direct oral anticoagulant (DOAC) like apixaban.
Answer: B. Continue the heparin infusion and maintain the current warfarin dose,
as the INR has not reached the therapeutic target range.
Rationale: When transitioning a patient from heparin to warfarin, "bridging" therapy is
required because warfarin has a delayed onset of action, taking several days to deplete
functional vitamin K-dependent clotting factors (II, VII, IX, X). The heparin infusion must
be continued concurrently until the INR reaches the designated therapeutic target range
(typically 2.5–3.5 for a mechanical aortic valve) and remains stable for at least 24 hours.
, Question 8
An acute care nurse practitioner is preparing to initiate an intravenous loading dose of
amiodarone for a patient experiencing an acute onset of hemodynamically stable
ventricular tachycardia. Which of the following baseline organ assessments is a priority
before initiating chronic maintenance therapy with this class III antiarrhythmic?
A. Pulmonary function tests and thyroid panel evaluation
B. Serological amylase and lipase profiles
C. Serum uric acid and joint fluid analysis
D. Structural bone mineral density scanning
Answer: A. Pulmonary function tests and thyroid panel evaluation
Rationale: Amiodarone is an iodine-rich medication that carries severe boxed warnings
for cumulative organ toxicity. It can cause fatal pulmonary toxicity (interstitial
pneumonitis or fibrosis) and significant thyroid dysfunction (hypothyroidism or
hyperthyroidism) due to its structural iodine content and inhibitory effects on thyroid
hormone conversion. Baseline and periodic pulmonary function tests (PFTs) and thyroid
panels are mandatory.
Question 9
A patient admitted with an acute myocardial infarction develops severe bradycardia with
a heart rate of 35 beats per minute and signs of hemodynamic compromise. The acute
care practitioner administers intravenous atropine sulfate. What is the molecular
mechanism of action of this drug?
A. Direct stimulation of beta-1 adrenergic receptors in the SA node
B. Competitive antagonism of muscarinic acetylcholine receptors blocking vagal tone
C. Inhibition of acetylcholinesterase to increase synaptic acetylcholine accumulation
D. Activation of peripheral alpha-1 receptors to cause compensatory vasoconstriction
Answer: B. Competitive antagonism of muscarinic acetylcholine receptors
blocking vagal tone
Rationale: Atropine is an anticholinergic medication that acts as a competitive
antagonist at muscarinic acetylcholine receptors. In symptomatic bradycardia, it blocks
the parasympathetic (vagal) input to the sinoatrial (SA) and atrioventricular (AV) nodes.
This inhibition removes the vagal brake on the heart, resulting in an increased sinus
heart rate and accelerated AV nodal conduction.
Question 10
A patient in the intensive care unit requires deep sedation and is prescribed a
continuous intravenous infusion of propofol. Which of the following metabolic monitoring
parameters must be closely evaluated due to the unique lipid emulsion formulation of
this anesthetic agent?
A. Serum uric acid and purine profiles
B. Serum triglycerides and total calorie counts from lipids
C. Blood urea nitrogen and creatinine clearance ratios
D. Serum calcium and parathyroid hormone levels
Answer: B. Serum triglycerides and total calorie counts from lipids
Rationale: Propofol is formulated in a phospholipid lipid emulsion containing soybean oil
and egg phosphatide, which delivers approximately 1.1 kcal/mL of fat. Prolonged or
high-dose infusions can cause significant hypertriglyceridemia and place the patient at
risk for propofol infusion syndrome (PRIS) or acute pancreatitis. Serum lipid panels
